Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) went down by -2.74% from its latest closing price compared to the recent 1-year high of $2.46. The company’s stock price has collected -29.00% of loss in the last five trading sessions. Press Release reported on 02/11/21 that Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)
Is It Worth Investing in Tonix Pharmaceuticals Holding Corp. (NASDAQ :TNXP) Right Now?
Plus, the 36-month beta value for TNXP is at 1.49. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Tonix Pharmaceuticals Holding Corp. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $3.00. TNXP currently public float of 156.47M and currently shorts hold a 1.93% ratio of that float. Today, the average trading volume of TNXP was 39.51M shares.
TNXP’s Market Performance
TNXP stocks went down by -29.00% for the week, with a monthly jump of 52.89% and a quarterly performance of 140.84%, while its annual performance rate touched 214.72%. The volatility ratio for the week stands at 13.66% while the volatility levels for the past 30 days are set at 15.37% for Tonix Pharmaceuticals Holding Corp.. The simple moving average for the period of the last 20 days is 8.11% for TNXP stocks with a simple moving average of 72.25% for the last 200 days.
Analysts’ Opinion of TNXP
Many brokerage firms have already submitted their reports for TNXP stocks, with ROTH Capital repeating the rating for TNXP by listing it as a “Buy.” The predicted price for TNXP in the upcoming period, according to ROTH Capital is $4 based on the research report published on April 18th of the previous year 2019.
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $6. The rating they have provided for TNXP stocks is “Buy” according to the report published on August 18th, 2017.
TNXP Trading at 47.94% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.28% of loss for the given period.
Volatility was left at 15.37%, however, over the last 30 days, the volatility rate increased by 13.66%, as shares surge +44.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +102.86% upper at present.
During the last 5 trading sessions, TNXP fell by -29.00%, which changed the moving average for the period of 200-days by +97.52% in comparison to the 20-day moving average, which settled at $1.3355. In addition, Tonix Pharmaceuticals Holding Corp. saw 110.37% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at TNXP starting from LEDERMAN SETH, who purchase 35,000 shares at the price of $0.68 back on Dec 30. After this action, LEDERMAN SETH now owns 118,267 shares of Tonix Pharmaceuticals Holding Corp., valued at $23,800 using the latest closing price.
Treco James, the Director of Tonix Pharmaceuticals Holding Corp., purchase 5,500 shares at $0.89 during a trade that took place back on Aug 31, which means that Treco James is holding 10,000 shares at $4,895 based on the most recent closing price.
Stock Fundamentals for TNXP
The total capital return value is set at -172.42, while invested capital returns managed to touch -172.99. Equity return is now at value -118.20, with -106.20 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp. (TNXP), the company’s capital structure generated 3.80 points at debt to equity in total, while total debt to capital is 3.66. Total debt to assets is 2.46, with long-term debt to equity ratio resting at 0.06. Finally, the long-term debt to capital ratio is 0.06.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.72.